Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGS07
- Development stage
- Preclinical
- Lead developer
- Ignis Therapeutics
01
Overview
IGS07 is an investigational therapeutic candidate currently in the preclinical stage of development by Ignis Therapeutics for the treatment of neuropathic pain. Ignis Therapeutics, a biotechnology company focused on central nervous system (CNS) disorders, has not publicly disclosed the specific molecular target, mechanism of action, or modality (e.g., small molecule or biologic) for this program. The asset is part of the company's early-stage pipeline aimed at addressing unmet medical needs in neurology and pain management, particularly within the Chinese market where Ignis operates as a joint venture between SK Biopharmaceuticals and a consortium led by 6 Dimensions Capital.
Beyond the preview
Go deeper on IGS07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGS07.